GlaxoSmithKline Pharmaceuticals Ltd today posted 42.87 per cent decline in its net profit at Rs 96.54 crore for the first quarter ended March 31, 2014, as the company continued to be impacted by the revamped price control order.
The company had registered a net profit of Rs 169.01 crore during the same period last year.
- Here’s What Farhan Akhtar Said On Karan Johar-MNS ‘Deal’ Over Ae Dil Hai Mushkil’s Release
- Government’s Diwali Gift to Central Government Employees, Pensioners
- Bigg Boss 10 26th October Review: This Episode Is All About Fights
- New Zealand Beat India By 19 Runs In Ranchi; Series Levelled At 2-2
- DND Toll-Free: Noida Toll Company Moves Supreme Court Against Allahabad High Court
- British PM Theresa May Says Kashmir Is A Matter For India, Pakistan To Sort Out
- J&K: Students Suffer As Schools Along LOC Forced To Shut Amid Firing
- Jayalalithaa’s Health: AIADMK Women Supporters Continue Special Prayers For CM
- HTC Desire 10 Lifestyle First Look Video
- Fissures Remain Within Samajwadi Party: All You Need To Know
- Big Cheer For Delhi-Noida Commuters, DND Flyway Becomes Toll Free
- PM Modi Meets New Zealand Prime Minister John Key
- Ex-Arunachal CM Kalikho Pul Left Behind “Secret Notes” Before He Was Found Hanging: Rajkhowa
- Big Relief For Former Karnataka CM BS Yeddyurappa: Here’s Why
- Missing For Three Days, JNU Student Found Dead In Hostel Room
Net sales of the company declined to Rs 599.85 crore for the first quarter, as compared to Rs 632.14 crore in the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
The company follows a January-December financial year.
“The quarter ended march 31, 2014, continued to see the impact of the revamped price control order, extending coverage to the National List of Essential Medicines (NLEM),” the company said.
Last year, Department of Pharmaceuticals had notified the Drugs (Prices Control) Order 2013 under which prices of 348 medicines in the NLEM have been brought under price control, thus replacing an earlier order of 1995 that regulated prices of only 74 bulk drugs.
Shares of GlaxoSmithKline Pharma closed at Rs 2,497.40 apiece, down 0.43 per cent on the BSE.